Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis
Henrik Watz,1 Kathleen Rickard,2 Tara Rheault,2 Thomas Bengtsson,3 Dave Singh4 1Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; 2Verona Pharma Plc, Raleigh, NC, USA; 3StatMind...
Main Authors: | Watz H, Rickard K, Rheault T, Bengtsson T, Singh D |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/symptom-improvement-following-treatment-with-the-inhaled-dual-phosphod-peer-reviewed-article-COPD |
Similar Items
-
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
by: Dave Singh, et al.
Published: (2020-02-01) -
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
by: Ferguson GT, et al.
Published: (2021-04-01) -
Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review
by: Martin C, et al.
Published: (2021-08-01) -
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
by: Dave Singh, et al.
Published: (2019-08-01) -
Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
by: Zhang X, et al.
Published: (2018-08-01)